Pharma Serialization: First Experience, Best Practices, Future Direction

FDA Finalizes the Definitions of 'Suspect and Illegitimate' Pharma Products

HDA’s 2023 Distribution Management Conference Dives into DSCSA Specifics and More

NABP Hopes to Fill a Key Gap in DSCSA Compliance: Local Pharmacies